CalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Key Highlights
- ➤CalciMedica management will participate in Guggenheim’s healthcare innovation conference November 10, 2026
- ➤Auxora has been evaluated in more than 350 patients
- ➤Auxora planned for Phase 1b pulmonary hypertension and Phase 2b acute pancreatitis trials
- ➤CM5480 IND submission for pulmonary hypertension anticipated in mid-2027
LA JOLLA, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CalciMedica, Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on Tuesday, November 10, 2026, at 9:30 a.m. ET.
A live webcast of the presentation can be accessed in the "IR Events and Presentations" section of CalciMedica's IR website. A replay of the webcast will be archived on the Company's website for 90 days.
Get started
Create a free account to read the full story.